Annexin A10 Expression in Hyperplastic Polyp, Sessile Serrated Adenoma Polyp and Conventional Adenoma

2018 ◽  
Vol 24 (9) ◽  
pp. 6376-6380
Author(s):  
Falaivi Farida ◽  
Handjari Diah Rini ◽  
Rahadiani Nur
2007 ◽  
Vol 131 (3) ◽  
pp. 440-445
Author(s):  
Shuan C. Li ◽  
Lawrence Burgart

Abstract Context.—Serrated adenomas can be morphologically subdivided into traditional and sessile types. They are thought to have a comparable rate of cancer progression like conventional adenomas, but they potentially have a faster rate of growth through methylation pathway(s). They share similar morphologic features with both the conventional adenoma and the hyperplastic polyp in a fashion that is different from a mixed adenoma and a hyperplastic polyp. Objective.—To describe the histopathologic features of traditional serrated adenoma and sessile serrated adenoma and their comparison with traditional adenomas and hyperplastic polyp. Data Sources.—Relevant articles in peer-review journals and the authors' working experience as practicing surgical pathologists with a specific interest in gastrointestinal pathology. Conclusions.—Both types of serrated adenomas, traditional serrated adenoma and sessile serrated adenoma, are morphologically distinct, clinically important entities, and they can be diagnosed accurately in routine practice.


2021 ◽  
pp. 1-7
Author(s):  
Meng-Lin Zhang ◽  
Wen-Juan Huang ◽  
Chen-Xi Yue ◽  
Ming-Ming Li ◽  
Na Li ◽  
...  

BACKGROUND: Platelets play a key role in tumor progression and metastasis. C-type lectin-like receptor 2 (CLEC-2) is the receptor expressed on platelets and the marker of platelet activation. OBJECTIVE: This study aims to determine whether soluble CLEC-2 levels differ between patients with benign colorectal polyps and those with colorectal cancer (CRC). METHODS: We measured plasma soluble CLEC-2 by enzyme-linked immunosorbent assay in 150 patients with colorectal polyps, 150 CRC patients without metastasis, 150 CRC liver metastasis, and 150 control subjects. RESULTS: The CRC patients had higher soluble CLEC-2 levels than patients with colorectal polyps (p< 0.001). Moreover, CRC patients with liver metastases displayed higher CLEC-2 levels than those in CRC patients without metastases (p< 0.001). In the CRC patients, CLEC-2 levels were correlated with lymph node metastasis and advanced stage. In the patients with polyps, there was a significant difference in CLEC-2 levels among patients with hyperplastic polyp, sessile serrated adenoma, and traditional serrated adenoma (p< 0.001). The ROC curve analysis revealed CLEC-2 had an optimal sensitivity of 77.3% and specificity of 94.6% for the screening of CRC, and sensitivity of 71.0% and specificity of 76.7% for the differential diagnosis of colorectal polyps and CRC. CONCLUSIONS: CRC patients have higher CLEC-2 levels than patients with colorectal polyps and healthy controls. Moreover, there is a significant difference in CLEC-2 levels among polyp subtypes. Further research is warranted.


2013 ◽  
Vol 66 (5) ◽  
pp. 403-408 ◽  
Author(s):  
Mahin Mohammadi ◽  
Michael Bzorek ◽  
Jesper Hansen Bonde ◽  
Hans J Nielsen ◽  
Susanne Holck

Non-dysplastic serrated polyps (ND-SP) represent a heterogeneous group of colorectal lesions that comprise hyperplastic polyp (HP) and the non-dysplastic subset of sessile serrated adenoma/polyp/lesion (SSA/P/L) and its borderline variant (BSSA/P/L). Given the observer variation in their histological typing, the identification of reliable markers that assist in the characterisation is warranted. Most important is the identification of polyp qualities that may reflect the patients’ risk of developing colorectal cancer. To address these issues, CD133 may represent a potential adjunct. Here we studied the discriminatory value of CD133 expression in the classification of ND-SPs and its distribution pattern in relation to synchronous colorectal carcinoma (SCRC). 39 SSA/P/Ls, 27 BSSA/P/Ls and 21 matched HPs were immunostained for CD133. The data were further correlated to the presence of SCRC and to polyp site and size. Ignoring SCRC status, CD133 was expressed more prominently in SSA/P/Ls than in HPs. The values for BSSA/P/Ls fell in between, yet closer to the SSA/P/L scorings. This observation was retained in the context of SCRC and for SSA/P/Ls not associated with SCRC. Right-sidedness and large size of the polyps more commonly associated with increased CD133 expression. CD133 expression was not a significant discriminator as to the SCRC status. BSSA/P/Ls are more closely aligned to SSA/P/L and further that SSA/P/L and BSSA/P/Ls fundamentally differ from HP by their CD133 immunoprofile, a notion that can be exploited in the diagnostic routine practice. Recorded data further indirectly support the idea that SSA/P/Ls are more prone to neoplastic progression than are HPs.


Sign in / Sign up

Export Citation Format

Share Document